Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Trump Praises FDA, But May Leave Firms Queasy With Pricing, Right-To-Try Comments

Executive Summary

State of the Union address touts FDA's record number of approvals, but also endorses right to try proposals and renews president's call for lower drug prices.

You may also be interested in...

Drug Importation Can Be Triggered By 'Excessive' Price Increases; Now US FDA Has To Decide What That Means

Did FDA Commissioner Scott Gottlieb and HHS Secretary Alex Azar have a change of heart on importation? Or are they being pressured from above?

Trump Emphasizes Foreign Drug Prices At Alex Azar's Swearing In

HHS secretary will get US drug prices 'way down … because it’s very unfair to our country,' president says. Also, 'we’re going to be very tough' on drug companies in combating the opioid crisis, Trump says.

US FDA Commissioner A 'Star' At Davos: Hopefully Not A Bad Omen

President Trump singles out Scott Gottlieb during dinner meeting at World Economic Forum. Does that make anyone else nervous?

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts